Search Patents
-
Patent number: 6287756Abstract: The invention relates to members of the SSX family of genes, as well as to their uses.Type: GrantFiled: June 26, 1998Date of Patent: September 11, 2001Assignee: Ludwig Institute for Cancer ResearchInventors: Özlem Türeci, Yao-Tseng Chen, Ugur Sahin, Ali O. Gure, Lloyd J. Old, Michael Pfreundschuh
-
Publication number: 20140134165Abstract: The present technology relates to genetic products the expression of which is associated with cancer diseases. The present technology also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.Type: ApplicationFiled: January 20, 2014Publication date: May 15, 2014Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski
-
Publication number: 20090253775Abstract: The present invention relates to methods which make possible to assess and/or prognose a cancer disease, the metastatic behaviour of a cancer disease and/or the occurrence of a relapse of cancer. In particular, the methods of the invention make possible to assess and/or prognose the occurrence of cancer metastasis, in particular distant metastasis. Preferably, the methods of the invention allow to discriminate malign from benign conditions.Type: ApplicationFiled: April 8, 2009Publication date: October 8, 2009Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski
-
Publication number: 20090155817Abstract: The invention relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the invention also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.Type: ApplicationFiled: December 3, 2008Publication date: June 18, 2009Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski
-
Publication number: 20120070430Abstract: The invention relates to genetic products the expression of which is associated with cancer diseases. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases.Type: ApplicationFiled: April 22, 2010Publication date: March 22, 2012Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski
-
Publication number: 20090252714Abstract: According to the invention, autoantibodies, the appearance of which is characteristic of neurological autoimmune diseases, especially multiple sclerosis, are detected and the respective autoantigens identified. It can further be shown that many of these autoantigens are expressed specifically in the brain. The identification of the autoantigens and autoantibodies is useful for diagnosis and treatment. A brain-specific expression of the autoantigens further emphasizes an important role of the antigens and antibodies in the origin and development of neurological autoimmune diseases.Type: ApplicationFiled: April 8, 2009Publication date: October 8, 2009Inventors: Ugur Sahin, Ozlem Tureci, Alexander Zaigler
-
Patent number: 7429461Abstract: The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which said genetic products that are expressed in association with a tumor are expressed in an aberrant manner. The invention also relates to proteins, polypeptides, and peptides which are expressed in association with a tumor and the nucleic acids coding therefor.Type: GrantFiled: March 12, 2003Date of Patent: September 30, 2008Assignee: Ganymed Pharmaceuticals AGInventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski
-
Patent number: 7527933Abstract: The invention relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the invention also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.Type: GrantFiled: November 21, 2003Date of Patent: May 5, 2009Assignee: Ganymed Pharmaceuticals AGInventors: Ugur Sahin, Ozlem Türeci, Michael Koslowski
-
Publication number: 20090214550Abstract: The invention relates to identifying tumor-associated genetic products and encoding nucleic acids thereof. A therapy and diagnosis of diseases in which the tumor-associated genetic products are aberrantly expressed, proteins, polypeptides and peptides which are expressed in association with tumor and the encoding nucleic acids for said proteins, polypeptides and peptides are also disclosed.Type: ApplicationFiled: March 23, 2006Publication date: August 27, 2009Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski, Gerd Helftenbein, Dirk Usener, Volker Schlüter
-
Patent number: 8765389Abstract: The invention relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for said products. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors and to the coding nucleic acids for said proteins, polypeptides and peptides.Type: GrantFiled: September 10, 2004Date of Patent: July 1, 2014Assignee: Ganymed Pharmaceuticals AGInventors: Öezlem Tüereci, Ugur Sahin, Michael Koslowski
-
Patent number: 8088588Abstract: The invention relates to the identification of genetic products expressed in association with tumors and to coding nucleic acids for the expressed products. An embodiment of the invention also relates to the therapy and diagnosis of disease in which the genetic products are aberrantly expressed in association with tumors, proteins, polypeptides and peptides which are expressed in association with tumors, and to the nucleic acids coding for the polypeptides, peptides and proteins.Type: GrantFiled: December 3, 2008Date of Patent: January 3, 2012Assignee: Ganymed Pharmaceuticals AGInventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
-
Patent number: 9775785Abstract: According to the invention, gene products expressed in a tumor-associated manner and the nucleic acids coding therefor were identified. The invention relates to the therapy and diagnosis of diseases wherein said gene products expressed in a tumor-associated manner are aberrantly expressed. The invention also relates to proteins, polypeptides and peptides which are expressed in a tumor associated manner and to nucleic acids coding therefor.Type: GrantFiled: April 1, 2015Date of Patent: October 3, 2017Assignee: GANYMED PHARMACEUTICALS AGInventors: Ozlem Tureci, Ugur Sahin, Michael Koslowski, Stephan Fritz, Harald-Gerhard Geppert
-
Patent number: 8399210Abstract: According to the invention, autoantibodies, the appearance of which is characteristic of neurological autoimmune diseases, especially multiple sclerosis, are detected and the respective autoantigens identified. It can further be shown that many of these autoantigens are expressed specifically in the brain. The identification of the autoantigens and autoantibodies is useful for diagnosis and treatment. A brain-specific expression of the autoantigens further emphasizes an important role of the antigens and antibodies in the origin and development of neurological autoimmune diseases.Type: GrantFiled: April 8, 2009Date of Patent: March 19, 2013Assignees: Ganymed Pharmaceuticals AG, Johannes Gutenberg-UniversitatInventors: Ugur Sahin, Özlem Türeci, Alexander Zaigler
-
Patent number: 11739139Abstract: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.Type: GrantFiled: July 2, 2020Date of Patent: August 29, 2023Assignees: Astellas Pharma Inc., TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTInventors: Ugur Sahin, Özlem Türeci, Dirk Usener, Stefan Fritz, Christoph Uherek, Gunda Brandenburg, Harald-Gerhard Geppert, Anja Kristina Schröder, Phillippe Thiel
-
Patent number: 7785801Abstract: The invention relates to the identification of gene products that are the result of tumor-associated expression and the nucleic acids encoding the same. The invention also relates to the therapy and diagnosis of diseases wherein these gene products are the result of an aberrant tumor-associated expression. The invention also relates to the proteins, polypeptides and peptides that are the result of tumor-associated expression and to the nucleic acids encoding the same.Type: GrantFiled: May 11, 2005Date of Patent: August 31, 2010Assignee: Ganymed Pharmaceuticals, AGInventors: Özlem Türeci, Ugur Sahin, Sandra Schneider, Gerd Helftenbein, Volker Schlüter, Dirk Usener, Philippe Thiel, Michael Koslowski
-
Publication number: 20120165390Abstract: The present invention is directed to siRNA molecules which specifically target and cause RNAi-induced degradation of mRNA from TPTE genes, so that the protein product of the TPTE gene is not produced or is produced in reduced amounts. The siRNA compounds and compositions of the invention are useful for treating diseases which require inhibition of TPTE expression for their treatment, in particular cancer pathologies. The present invention also includes methods which make possible to assess and/or prognose the metastatic behaviour of a cancer disease and/or the occurrence of a relapse of cancer.Type: ApplicationFiled: November 21, 2011Publication date: June 28, 2012Applicants: JOHANNES GUTENBERG-UNIVERSITAT MAINZ, GANYMED PHARMACEUTICALS AGInventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
-
Publication number: 20110318264Abstract: The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of colorectal, in particular colonic, and gastric tumor tissues and colorectal, in particular colonic, and gastric tissues, and which represent targets for therapy or diagnosis of such tumor diseases in a subject.Type: ApplicationFiled: February 18, 2010Publication date: December 29, 2011Inventors: Ugur Sahin, Özlem Türecl, Michael Koslowski
-
Patent number: 6338947Abstract: The invention relates to assays for determining breast cancer or melanoma. It has been found that the accuracy of such assays can be improved by assaying samples for three or more known tumor rejection antigen precursors. For breast cancer, the tumor rejection antigen precursors known as SCP-1, NY-ESO-1, and SSX-2 are assayed. For melanoma, SSX-2, NY-ESO-1, and MAGE-3 are assayed. Additional known tumor rejection antigen precursors can also be determined to confirm the assays. It is preferred to carry these out via polymerase chain reactions.Type: GrantFiled: May 25, 2000Date of Patent: January 15, 2002Assignee: Ludwig Institute for Cancer ResearchInventors: Ugur Sahin, Özlem Türeci, Yao-Tseng Chen, Lloyd J. Old, Michael Pfreundschuh
-
Patent number: 10526387Abstract: The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.Type: GrantFiled: November 2, 2016Date of Patent: January 7, 2020Assignees: BIONTECH PROTEIN THERAPEUTICS GMBH, TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVRESITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBHInventors: Thorsten Klamp, Ugur Sahin, Ozlem Tureci, Michael Koslowski, Thomas Hiller, Jens Schumacher
-
Publication number: 20110014628Abstract: An isolated truncated desmoglein 4 (DSG4) polypeptide splice variant of the invention is characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75. Also disclosed is a method of diagnosing a cancer, or monitoring the course thereof, in a patient. The method comprises detecting in a tissue sample of a patient the expression of a tumor-associated antigen comprising the extracellular domain of a DSG4 polypeptide encoded by a DSG4 gene having the polynucleotide sequence of SEQ ID NO: 75, or a truncated DSG4 polypeptide splice variant characterized by an amino acid sequence that lacks a region encoded before exon 9 or beyond exon 10 of the DSG4 gene.Type: ApplicationFiled: August 6, 2010Publication date: January 20, 2011Applicant: GANYMED PHARMACEUTICALS, AGInventors: Özlem TÜRECI, Ugur SAHIN, Sandra SCHNEIDER, Gerd HELFTENBEIN, Volker SCHLÜTER, Dirk USENER, Philippe THIEL, Michael KOSLOWSKI